contact us
Eli Lilly's drug for treating axial spondyloarthritis, a chronic inflammatory disease affecting predominantly the sacroiliac joints and the axial skeleton, meets both primary and secondary endpoints in a Phase 3 study.
Do Not Allow Advertisers to Use My Personal information